Drugs / MF59
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06417853 | Jul 2024 → Jan 2026 | avian influenza | Vaxxas Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05875961 | Jun 2023 → Nov 2024 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 1 | NCT03014310 | Jan 2017 → Dec 2018 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02298179 | Dec 2014 → Mar 2017 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00912496 | Jun 2010 → Dec 2011 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00001042 | ? → Mar 1996 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05608005 | Nov 2022 → Feb 2023 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT00379938 | Aug 2006 → Oct 2008 | Parvoviridae infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00280033 | Feb → Nov 2006 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06560151 | Aug 2024 → Jan 2025 | influenza | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
| Phase 2 | NCT03682120 | Nov 2018 → Apr 2020 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT03283319 | Sep → Dec 2017 | influenza | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
| Phase 2 | NCT01942265 | Sep 2013 → Jan 2015 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01938742 | Sep 2013 → Nov 2014 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07126652 | Oct 2025 → Dec 2026 expected | — | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 1 | NCT07421037 Background | Nov 2025 → Dec 2026 expected | influenza | Ab&B Bio-tech Co., Ltd.JS | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07421050 Background | Nov 2025 → Dec 2026 expected | influenza | Ab&B Bio-tech Co., Ltd.JS | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01418235 Background | Dec 2011 → Oct 2013 | — | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT00848848 Comparator | Oct 2008 → Apr 2009 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 1 | NCT00000832 Background | ? → Jan 1998 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000868 Background | ? → May 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT03284710 Comparator | Jun 2017 → Dec 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02213354 Background | Oct 2014 → Jul 2016 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01097096 Comparator | Mar 2010 → Dec 2012 | Alzheimer disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00133497 Background | Jun 2006 → Jun 2013 | cytomegalovirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00125502 Background | Aug 1999 → Jun 2007 | cytomegalovirus infection | Robert Pass, MD | Completed | Met primary |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-09-10 | CSL Behring | Results Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults csl.com ↗
The peer-reviewed publication reports findings from a large-scale study of the first influenza vaccine to combine three proven approaches to enhancing protection in older adults: MF59 ® adjuvant, cell-based manufacturing, and a higher dose formulation compared to standard influenza vaccines. |
| 2022-10-05 | CSL Behring | Results CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates csl.com ↗
In comparison to the MF59®-adjuvanted influenza vaccine and non-adjuvanted protein vaccine, the adjuvanted influenza vaccine also raised CD4+ T cell response, while the non-adjuvanted protein vaccine did not. |
| 2022-09-26 | CSL Behring | Results New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems csl.com ↗
CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems. |
| 2020-12-14 | CSL Behring | Results Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Value of MF59®-Adjuvanted Seasonal Influenza Vaccine csl.com ↗
Results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters. |
| 2019-12-09 | CSL Behring | Results New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine csl.com ↗
Moreover, FLUAD was 20 percent more effective than TIV in reducing the rate of hospitalization for influenza and pneumonia (adjusted hazard ratio 0.80, 95% CI: 0.66, 0.98, p=0.03). |
| 2019-08-30 | CSL Behring | Results Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response csl.com ↗
Induced a higher immune response upon two revaccination studies as demonstrated for both homologous and heterologous strains in children (6 months to 72 months old) compared to a non-adjuvanted influenza vaccine |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MF59 | “3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22.” NCT03682120 ↗28“MF59®-adjuvanted influenza vaccines have superior immunogenicity in older adults compared with non-adjuvanted vaccines” PMID 22426371 ↗ Feb 2012 “7.5 mcg Influenza A (H7N9) with MF59® Injection” NCT06417853 ↗ “Microfluoridized adjuvant 59 (MF59).” NCT00133497 ↗ “MF59 adjuvant” NCT00912496 ↗ “MF59” NCT01097096 ↗ |
| Known as | MF59(R) | “3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22.” NCT03682120 ↗ |
| Modality | Other / unclassified | “MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines” PMID 24732325 ↗ Apr 2014 |
| Route | Intramuscular | “Healthy volunteers receive intramuscular injections of rgp120/HIV-1SF2 with MF59 adjuvant emulsion or MF59 alone at months 0, 1, 6, 9, 10 and 12” NCT00000832 ↗ |